Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
DRRX [NASD]
DURECT Corporation
Healthcare | Drug Manufacturers - Specialty & Generic | USA
statements
Index- P/E- EPS (ttm)-0.17 Insider Own0.10% Shs Outstand227.50M Perf Week-13.27%
Market Cap154.67M Forward P/E- EPS next Y-0.16 Insider Trans9.50% Shs Float224.16M Perf Month-32.19%
Income-38.10M PEG- EPS next Q-0.05 Inst Own52.50% Short Float3.04% Perf Quarter-43.60%
Sales8.90M P/S17.38 EPS this Y40.10% Inst Trans-0.08% Short Ratio9.27 Perf Half Y-55.41%
Book/sh0.28 P/B2.36 EPS next Y5.60% ROA- Target Price6.00 Perf Year-70.67%
Cash/sh0.34 P/C1.91 EPS next 5Y15.00% ROE- 52W Range0.67 - 2.95 Perf YTD-33.07%
Dividend- P/FCF- EPS past 5Y17.80% ROI-20.70% 52W High-77.61% Beta1.31
Dividend %- Quick Ratio8.90 Sales past 5Y9.50% Gross Margin83.20% 52W Low-1.51% ATR0.07
Employees79 Current Ratio9.10 Sales Q/Q22.20% Oper. Margin- RSI (14)22.28 Volatility8.85% 8.05%
OptionableYes Debt/Eq0.32 EPS Q/Q4.70% Profit Margin- Rel Volume1.25 Prev Close0.68
ShortableYes LT Debt/Eq0.32 EarningsNov 02 AMC Payout- Avg Volume735.84K Price0.66
Recom1.70 SMA20-23.80% SMA50-32.22% SMA200-51.16% Volume921,445 Change-2.93%
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Jul-12-17Upgrade Stifel Hold → Buy $1.25 → $3
Feb-28-17Resumed H.C. Wainwright Buy $3
Apr-25-16Initiated Rodman & Renshaw Buy $4
May-01-15Reiterated Stifel Buy $1.50 → $2.50
May-01-15Reiterated Cantor Fitzgerald Buy $2.50 → $3
Mar-25-13Initiated Stifel Buy $3
Nov-01-12Downgrade C.K. Cooper Buy → Hold $3
Aug-17-12Initiated C.K. Cooper Buy $3
Jun-23-09Initiated Caris & Company Buy $5
Mar-26-09Initiated Wedbush Morgan Hold
Jan-13-22 10:00AM  
Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks
Zacks
Jan-06-22 04:05PM  
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
PR Newswire
Dec-22-21 07:30AM  
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
PR Newswire
05:45AM  
Do Institutions Own DURECT Corporation (NASDAQ:DRRX) Shares?
Simply Wall St.
Dec-14-21 09:00AM  
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
PR Newswire
Nov-29-21 09:00AM  
DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit
PR Newswire
Nov-12-21 09:00AM  
Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.
PR Newswire -6.40%
Nov-10-21 09:00AM  
DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis
PR Newswire
Nov-08-21 09:00AM  
DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021
PR Newswire
Nov-07-21 07:45AM  
Health Check: How Prudently Does DURECT (NASDAQ:DRRX) Use Debt?
Simply Wall St.
Nov-02-21 06:15PM  
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
Zacks
04:05PM  
DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs
PR Newswire
Oct-26-21 09:00AM  
DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2
PR Newswire
Oct-25-21 03:01PM  
Will Durect (DRRX) Report Negative Q3 Earnings? What You Should Know
Zacks
Oct-07-21 09:00AM  
DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference
PR Newswire
Sep-23-21 09:00AM  
DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021
PR Newswire
Sep-15-21 09:00AM  
DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit
PR Newswire
Sep-07-21 09:00AM  
DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference
PR Newswire
Aug-09-21 05:29AM  
Would Shareholders Who Purchased DURECT's (NASDAQ:DRRX) Stock Year Be Happy With The Share price Today?
Simply Wall St.
Jul-29-21 07:25PM  
Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
Zacks
04:05PM  
DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs
PR Newswire
Jul-22-21 08:30AM  
DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29
PR Newswire
Jul-14-21 04:30PM  
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
PR Newswire -5.04%
Jun-25-21 09:37AM  
Here's What DURECT Corporation's (NASDAQ:DRRX) Shareholder Ownership Structure Looks Like
Simply Wall St. +7.06%
Jun-23-21 09:00AM  
DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)
PR Newswire
Jun-09-21 09:00AM  
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
PR Newswire
May-04-21 07:45PM  
Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates
Zacks -6.77%
04:05PM  
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs
PR Newswire
02:30PM  
DURECT Corp. to Host Earnings Call
ACCESSWIRE
Apr-27-21 08:30AM  
DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4
PR Newswire
Mar-09-21 09:00AM  
DURECT Corporation Announces Publication of DUR-928's Mechanism of Action
PR Newswire
Mar-04-21 05:31PM  
Durect: Q4 Earnings Insights
Benzinga -6.02%
05:25PM  
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
Zacks
02:30PM  
DURECT Corp. to Host Earnings Call
ACCESSWIRE
Mar-03-21 06:02PM  
DURECT Corporation to Participate in Three Investor Conferences in March 2021
PR Newswire -6.49%
Feb-04-21 09:18AM  
DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock
PR Newswire -15.68%
Feb-03-21 04:01PM  
DURECT Corporation Announces Proposed Offering of Common Stock
PR Newswire +15.73%
Feb-02-21 08:28AM  
Durect stock soars 34% after it gets FDA approval for surgical pain treatment
MarketWatch +18.10%
08:01AM  
DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
PR Newswire
Jan-25-21 08:30AM  
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis
PR Newswire +6.22%
Jan-05-21 08:30AM  
DURECT Corporation Appoints Two New Board Members
PR Newswire
Jan-04-21 08:30AM  
DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million
PR Newswire
Dec-21-20 08:30AM  
DURECT Corporation to Participate in Investor Conferences in January 2021
PR Newswire
Dec-16-20 08:30AM  
DURECT Corporation Announces DUR-928 Granted FDA Fast Track Designation for Treatment of Alcoholic Hepatitis
PR Newswire
Dec-09-20 01:33PM  
Is DRRX A Good Stock To Buy Now?
Insider Monkey
Dec-07-20 11:15AM  
DURECT Corporation to Sell its LACTEL® Absorbable Polymer Product Line to Evonik for $15 Million
PR Newswire
Nov-13-20 09:00AM  
DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020
PR Newswire
Nov-10-20 08:30AM  
DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman
PR Newswire
Nov-02-20 11:31PM  
Durect Corp (DRRX) Q3 2020 Earnings Call Transcript
Motley Fool
06:15PM  
Durect (DRRX) Reports Q3 Loss, Lags Revenue Estimates
Zacks
04:05PM  
DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs
PR Newswire
04:02PM  
DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer
PR Newswire
02:30PM  
DURECT Corp. to Host Earnings Call
ACCESSWIRE
07:35AM  
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
Zacks
Oct-27-20 08:30AM  
DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020
PR Newswire
Oct-26-20 04:30PM  
DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event "Covid-19 Therapeutics in Development"
PR Newswire
12:31PM  
Durect (DRRX) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
Oct-05-20 08:30AM  
DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience 2020
PR Newswire
Sep-30-20 04:53PM  
DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference
PR Newswire
Sep-23-20 08:30AM  
DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
PR Newswire
Sep-22-20 08:30AM  
DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM)
PR Newswire
Sep-10-20 08:30AM  
DURECT Corporation to Participate in September Virtual Investor Conferences
PR Newswire
Aug-27-20 08:30AM  
DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL)
PR Newswire -5.03%
Aug-26-20 04:30PM  
DURECT Corporation Fireside Chat hosted by Ellie Merle of Cantor Fitzgerald
PR Newswire
Aug-05-20 03:31PM  
Oppenheimer: These 3 Strong Buy Stocks Could Double, If Not More
TipRanks
08:30AM  
DURECT to Present at the BTIG Biotechnology Conference 2020
PR Newswire
Aug-04-20 01:00AM  
Durect Corp (DRRX) Q2 2020 Earnings Call Transcript
Motley Fool
Aug-03-20 06:35PM  
Durect (DRRX) Q2 Earnings and Revenues Beat Estimates
Zacks +19.64%
04:05PM  
DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
PR Newswire
Jul-28-20 08:30AM  
DURECT Corporation to Announce Second Quarter 2020 Financial Results and Provide Business Update on August 03
PR Newswire
Jul-07-20 07:35AM  
Is It Too Late to Buy These 3 Pharmaceutical Stocks?
Motley Fool
Jul-01-20 08:30AM  
DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
PR Newswire
Jun-29-20 09:00AM  
U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller
Reuters
08:30AM  
DURECT Corporation Joins the Russell 3000® Index
PR Newswire
Jun-26-20 05:15PM  
Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product
PR Newswire -11.23%
10:37AM  
DURECT Corporation (DRRX): Hedge Funds Are Nibbling
Insider Monkey
Jun-11-20 02:45PM  
Top Pharmaceutical Stocks for Q3 2020
Investopedia -8.15%
May-28-20 09:00AM  
DURECT to Present at the Jefferies 2020 Virtual Health Care Conference
PR Newswire -8.46%
May-26-20 08:30AM  
DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH
PR Newswire +7.69%
May-20-20 10:04AM  
Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks
TipRanks
May-12-20 03:00PM  
Durect Corp (DRRX) Q1 2020 Earnings Call Transcript
Motley Fool +21.33%
02:20PM  
Here's Why Shares of Durect Jumped Higher Today
Motley Fool
May-11-20 06:55PM  
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
Zacks
04:05PM  
DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs
PR Newswire
May-04-20 05:00PM  
DURECT Corporation to Announce First Quarter 2020 Financial Results and Provide Business Update on May 11
PR Newswire
Apr-28-20 12:33PM  
Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks
Mar-24-20 04:18PM  
Edited Transcript of DRRX earnings conference call or presentation 3-Mar-20 9:30pm GMT
Thomson Reuters StreetEvents +10.24%
Mar-03-20 04:05PM  
DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs
PR Newswire -9.95%
Feb-26-20 07:30AM  
DURECT Corporation to Announce 2019 Financial Results on March 3
PR Newswire
Feb-10-20 08:05AM  
3 Strong Buy Healthcare Stocks With Triple-Digit Upside
TipRanks +11.32%
Jan-31-20 11:14AM  
5 Stocks Under $5 With Colossal Growth Prospects
InvestorPlace
Jan-17-20 08:19AM  
UPDATE: Durect stock slides after FDA committee ends meeting with split vote on post-surgical pain treatment
MarketWatch
08:07AM  
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
Benzinga
06:45AM  
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR®
PR Newswire
Jan-16-20 02:38PM  
U.S. FDA panel split over approval of Durect's non-opioid painkiller
Reuters
07:24AM  
Biopharma Durect shares halted ahead of FDA committee meeting on post-surgical pain treatment
MarketWatch
07:05AM  
DURECT Corporation Trading Halted Today; FDA Advisory Committee to Discuss POSIMIR® (bupivacaine extended-release solution) for Post-Surgical Analgesia
PR Newswire
Jan-02-20 05:28PM  
Drug developer dips on failed psoriasis trial
American City Business Journals -31.18%
10:08AM  
Durect's stock tumbles after failed psoriasis trial
MarketWatch
09:00AM  
DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis
PR Newswire
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BENITO SIMON XDirectorDec 07Buy1.0220,00020,360105,000Dec 09 01:35 PM
Joice Judy RSr. VP Operations & Corp QAMay 14Option Exercise0.7660,13745,90794,969May 17 09:37 PM
Joice Judy RSr. VP Operations & Corp QAMay 14Sale1.7260,137103,68234,832May 17 09:37 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.